...
【24h】

Changing treatment and outcome of children with hepatoblastoma: Analysis of a single center experience over the last 20 years

机译:改变儿童肝母细胞瘤的治疗方法和结局:过去20年对一个中心经验的分析

获取原文
获取原文并翻译 | 示例

摘要

Background/Purpose: The aim of the study was to analyze changing management and survival of children with hepatoblastoma (HBL) treated in one center. Materials and Methods: Over the last 20 years, 51 children with HBL were treated. Surgery was performed in 48 children (94.1%), conventional liver resection in 38 (of those, 2 received a rescue liver transplantation [LTx] for relapse), and total hepatectomy and primary LTx in 10 patients. The remaining 3 patients received only palliative treatment. Patient data were analyzed for survival with respect to PRETreatment EXTent of disease (PRETEXT), metastases, histopathology, conventional resection, and LTx. Results: Survival of children with HBL treated with liver resection is 71% and 80% for primary LTx. Favorable prognostic factors for patient survival was tumor histology as epithelial-fetal subtype and mixed epithelial and mesenchymal type, without teratoid features, and good response to chemotherapy (necrosis, fibrosis). Unfavorable prognostic factors were small cells undifferentiated, transitional liver cell tumor, α-fetoprotein level above 1,000,000 IU/mL and below 100 IU/mL at diagnosis, lung metastases, and local recurrence after initial resection. Survival was related to PRETEXT stage. However, among patients with PRETEXT III and IV, LTx resulted in better survival. Conclusion: Liver transplantation is a good option for children with advanced HBL. Early referral of children with potentially unresectable tumors to centers where combined treatment (chemotherapy, surgery including LTx) is available is crucial.
机译:背景/目的:本研究的目的是分析在一个中心接受治疗的肝母细胞瘤(HBL)患儿的变化管理和生存情况。材料和方法:在过去的20年中,对51例HBL儿童进行了治疗。接受手术的儿童有48例(94.1%),常规的肝切除术有38例(其中2例因复发而接受了急诊肝移植[LTx]),并且有10例患者进行了全肝切除和原发性LTx。其余3例仅接受姑息治疗。分析患者数据的生存率,包括疾病的预治疗范围(PRETEXT),转移,组织病理学,常规切除和LTx。结果:经肝切除治疗的HBL患儿的生存率为71%,原发性LTx为80%。对患者生存有利的预后因素是肿瘤组织学,如上皮-胎儿亚型以及上皮和间质混合型,无畸胎样特征,对化疗反应良好(坏死,纤维化)。不利的预后因素是未分化的小细胞,移行性肝细胞肿瘤,诊断时的甲胎蛋白水平高于1,000,000 IU / mL而低于100 IU / mL,肺转移和初次切除后局部复发。生存与PRETEXT阶段有关。但是,在具有PRETEXT III和IV的患者中,LTx可以提高生存率。结论:肝移植是晚期HBL患儿的理想选择。至关重要的是,将可能无法手术切除的肿瘤的儿童尽早转至可以进行联合治疗(化学疗法,包括LTx在内的手术)的中心。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号